AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Article Link
Collect
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

Dosimetric comparison of AcurosBV with AAPM TG43 dose calculation formalism in cervical intraductal high-dose-rate brachytherapy using three different applicators

Su-yan BiZhi-jian ChenXing-ru SunZhi-tao Dai ( )
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
Show Author Information

Abstract

Purpose

To compare the dosimetric effects of American Association of Physicists in Medicine (AAPM) TG43 dose formalism and AcurosBV (grid-based Boltzmann solver, GBBS) formalism on high-dose-rate (HDR) brachytherapy planning for cervical cancer patients irradiated using three different applicators.

Methods

A TG43 plan and a AcurosBV plan were generated for each of the 30 patients. Twenty patients who had undergone whole pelvic radiotherapy followed by cervical HDR brachytherapy and the remaining 10 patients who underwent total hysterectomy only gave HDR brachytherapy also were enrolled in this study. The patients were divided into three groups according to the types of applicators used: tandem and ovoid (T & O), tandem and ring (T & R), and cylinder. To compare the dosimetric parameters, the cumulative dose-volume histograms (DVHs) were measured. We also compared the doses at 90% of the volume (D90%), the volume receiving 100% and 150% of the prescribed dose (V100% and V150%) for the clinical target volume (CTV-HR), and the doses of point A, the dose receiving 0.1 and 2 cc of the volume (D0.1cc and D2cc) for the organs-at-risk (OARs).

Results

Compared with the AcurosBV plans, TG43 plans predicted higher D90%, V100%, and V150% of CTV-HR, dose of point A, and D0.1cc and D2cc of OARs in three types of applicators. Except D2cc of sigmoid in T & R and cylinder applicators, the D90%, V100%, and V150% of CTV-HR; the dose of point A and the D0.1cc and D2cc of bladder, rectum, and small bowel exhibited significant discrepancies (all p < 0.05). The effects of the three types of applicators on the dose distribution were quite different due to the differences in the materials: The dose difference of CTV-HR and OARs was greatest (around 10%) for T & O applicators but only 1–5% for T & R and cylinder applicators.

Conclusions

AcurosBV was more accurate in calculating the doses in the air cavity and high-density substance than TG43. In the clinical setting, AcurosBV exhibited different dosimetric distributions in the cervix plans for HDR brachytherapy, especially in treatment planning when using T & O applicators. The AcurosBV algorithm should be considered when using T & O applicators or other materials with a much higher or lower density (metal or air) than soft tissue. However, If the density is close to that of soft tissue, considering AcurosBV algorithm requires more calculation time, TG43 could still be selected when using applicators in clinical.

References

1

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394-424.

2

Mabuchi Y, Takiguchi Y, Yahata T, et al. Short term outcomes of helical tomotherapy during concurrent chemoradiotherapy for advanced cervical cancer. Mol Clin Oncol. 2019; 10(3): 382-386.

3

Riou O, Regnault de la Mothe P, Azria D, Aillères N, Dubois JB, Fenoglietto P. Simultaneous integrated boost plan comparison of volumetric-modulated arc therapy and sliding window intensity-modulated radiotherapy for whole pelvis irradiation of locally advanced prostate cancer. J Appl Clin Med Phys. 2013; 14(4): 4094.

4

Nori D, Dasari N, Allbright RM. Gynecologic brachytherapy I: proper incorporation of brachytherapy into the current multimodality management of carcinoma of the cervix. Semin Radiat Oncol. 2002; 12(1): 40-52.

5

Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys. 1995; 22(2): 209-234.

6

Beaulieu L, Carlsson Tedgren A, Carrier JF, et al. Report of the Task Group 186 on model-based dose calculation methods in brachytherapy beyond the TG-43 formalism: current status and recommendations for clinical implementation. Med Phys. 2012; 39(10): 6208-6236.

7

Enger SA, Vijande J, Rivard MJ. Model-based dose calculation algorithms for brachytherapy dosimetry. Semin Radiat Oncol. 2020; 30(1): 77-86.

8

Georg D, Kirisits C, Hillbrand M, Dimopoulos J, Pötter R. Image-guided radiotherapy for cervix cancer: high-tech external beam therapy versus high-tech brachytherapy. Int J Radiat Oncol Biol Phys. 2008; 71(4): 1272-1278.

9

Sinnatamby M, Nagarajan V, Reddy K, Karunanidhi G, Singhavajala V. Comparison of image-based three-dimensional treatment planning using AcurosTM BV and AAPM TG-43 algorithm for intracavitary brachytherapy of carcinoma cervix. J Radiother Pract. 2016; 15(3): 254-262.

10

Cawston-Grant B, Morrison H, Menon G, Sloboda RS. Experimental verification of advanced collapsed-cone engine for use with a multichannel vaginal cylinder applicator. J Appl Clin Med Phys. 2017; 18(3): 16-27.

11

Pantelis E, Papagiannis P, Karaiskos P, et al. The effect of finite patient dimensions and tissue inhomogeneities on dosimetry planning of 192Ir HDR breast brachytherapy: a Monte Carlo dose verification study. Int J Radiat Oncol Biol Phys. 2005; 61(5): 1596-1602.

12

Lymperopoulou G, Pantelis E, Papagiannis P, et al. A monte carlo dosimetry study of vaginal 192Ir brachytherapy applications with a shielded cylindrical applicator set. Med Phys. 2004; 31(11): 3080-3086.

13

Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet. 2018; 143(2): 22-36.

14

Vízkeleti J, Fröhlich G, Nhung NA, Horváth K, Major T, Polgár C. Clinical results of combined intracavitary-interstitial image-guided adaptive brachytherapy in locally advanced cervical cancer. Magy Onkol. 2018; 62(4): 249-257.

15

Kirchheiner K, Nout RA, Tanderup K, et al. Manifestation pattern of early-late vaginal morbidity after definitive radiation (chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: an analysis from the EMBRACE study. Int J Radiat Oncol Biol Phys. 2014; 89(1): 88-95.

16

Georg P, Pötter R, Georg D, et al. Dose effect relationship for late side effects of the rectum and urinary bladder in magnetic resonance image-guided adaptive cervix cancer brachytherapy. Int J Radiat Oncol Biol Phys. 2012; 82(2): 653-657.

17

Papagiannis P, Pantelis E, Karaiskos P. Current state of the art brachytherapy treatment planning dosimetry algorithms. Br J Radiol. 2014; 87: 20140163. https://doi.org/10.1259/bjr.20140163

18

Boman EL, Satherley TWS, Schleich N, Paterson DB, Greig L, Louwe RJW. The validity of Acuros BV and TG-43 for high-dose-rate brachytherapy superficial mold treatments. Brachytherapy. 2017; 16(6): 1280-1288.

19

Pötter R, Dimopoulos J, Georg P, et al. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother Oncol. 2007; 83(2): 148-155.

20

Lang S, Kirisits C, Dimopoulos J, Georg D, Pötter R. Treatment planning for MRI assisted brachytherapy of gynecologic malignancies based on total dose constraints. Int J Radiat Oncol Biol Phys. 2007; 69(2): 619-627.

21

Dagli A, Yurt F, Dagli G, Yurt F, Yegin G. Evaluation of BrachyDose Monte Carlo code for HDR brachytherapy: dose comparison against Acuros®BV and TG-43 algorithms. J Radiother Pract. 2020; 19(1): 76-83.

22

Fröhlich G, Geszti G, Vízkeleti J, Ágoston P, Polgár C, Major T. Dosimetric comparison of inverse optimisation methods versus forward optimisation in HDR brachytherapy of breast, cervical and prostate cancer. Strahlenther Onkol. 2019; 195(11): 991-1000.

23

Koo T, Chung JB, Eom KY, Seok JY, Kim IA, Kim JS. Dosimetric effects of the acuros XB and anisotropic analytical algorithm on volumetric modulated arc therapy planning for prostate cancer using an endorectal balloon. Radiat Oncol. 2015; 10: 48.

24

Moura ES, Micka JA, Hammer CG, et al. Development of a phantom to validate high-dose-rate brachytherapy treatment planning systems with heterogeneous algorithms. Med Phys. 2015; 42(4): 1566-1574.

25

Jacob D, Lamberto M, DeSouza Lawrence L, Mourtada F. Clinical transition to model-based dose calculation algorithm: a retrospective analysis of high-dose-rate tandem and ring brachytherapy of the cervix. Brachytherapy. 2017; 16(3): 624-629.

26

Petrokokkinos L, Zourari K, Pantelis E, et al. Dosimetric accuracy of a deterministic radiation transport based 192Ir brachytherapy treatment planning system. Part II: Monte Carlo and experimental verification of a multiple source dwell position plan employing a shielded applicator. Med Phys. 2011; 38(4): 1981-1992.

27

Zourari K, Pantelis E, Moutsatsos A, et al. Dosimetric accuracy of a deterministic radiation transport based (192)Ir brachytherapy treatment planning system. Part III. Comparison to Monte Carlo simulation in voxelized anatomical computational models. Med Phys. 2013; 40(1). https://doi.org/10.1118/1.4770275

28

Abe K, Kadoya N, Sato S, et al. Impact of a commercially available model-based dose calculation algorithm on treatment planning of high-dose-rate brachytherapy in patients with cervical cancer. J Radiat Res. 2018; 59(2): 198-206.

29

Hofbauer J, Kirisits C, Resch A, et al. Impact of heterogeneity-corrected dose calculation using a grid-based Boltzmann solver on breast and cervix cancer brachytherapy. J Contemp Brachytherapy. 2016; 8(2): 143-149.

30

Mikell JK, Klopp AH, Gonzalez GM, et al. Impact of heterogeneity-based dose calculation using a deterministic grid-based Boltzmann equation solver for intracavitary brachytherapy. Int J Radiat Oncol Biol Phys. 2012; 83(3): e417-422.

31

Carrier JF, Beaulieu L, Therriault-Proulx F, Roy R. Impact of interseed attenuation and tissue composition for permanent prostate implants. Med Phys. 2006; 33(3): 595-604.

32

Lymperopoulou G, Papagiannis P, Angelopoulos A, Karaiskos P, Georgiou E, Baltas D. A dosimetric comparison of 169Yb and 192Ir for HDR brachytherapy of the breast, accounting for the effect of finite patient dimensions and tissue inhomogeneities. Med Phys. 2006; 33(12): 4583-4589.

33
Papanikolaou N, Battista J, Boyer A, et al. Tissue inhomogeneity corrections for megavoltage photon beams. AAPM Report No. 85, Task Group No 65 of the Radiation Therapy Committee of the American Association of Physicists in Medicine. 2004.
34

Ahnesjö A. Collapsed cone convolution of radiant energy for photon dose calculation in heterogeneous media. Med Phys. 1989; 16(4): 577-592.

35

Rogers DW. Fifty years of Monte Carlo simulations for medical physics. Phys Med Biol. 2006; 51(13): R287-301.

36

Gifford KA, Horton JL, Wareing TA, Failla G, Mourtada F. Comparison of a finite-element multigroup discrete-ordinates code with Monte Carlo for radiotherapy calculations. Phys Med Biol. 2006; 51(9): 2253-2265.

37

Vassiliev ON, Wareing TA, McGhee J, Failla G, Salehpour MR, Mourtada F. Validation of a new grid-based Boltzmann equation solver for dose calculation in radiotherapy with photon beams. Phys Med Biol. 2010; 55(3): 581-598.

Precision Radiation Oncology
Pages 234-242
Cite this article:
Bi S-y, Chen Z-j, Sun X-r, et al. Dosimetric comparison of AcurosBV with AAPM TG43 dose calculation formalism in cervical intraductal high-dose-rate brachytherapy using three different applicators. Precision Radiation Oncology, 2022, 6(3): 234-242. https://doi.org/10.1002/pro6.1170

387

Views

1

Crossref

2

Scopus

Altmetrics

Received: 07 July 2022
Accepted: 07 August 2022
Published: 31 August 2022
© 2022 The Authors. Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Return